title: IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus.
abstract: OBJECTIVE
  To assess the functional status of the IL-15/IL-15Ralpha cytokine system in different leucocyte subsets from patients with systemic lupus erythematosus (SLE).
  
  
  METHODS
  Eighteen patients with SLE (10 with inactive and eight with active disease) and 14 healthy individuals were studied. Serum levels and in vitro production of IL-15 were determined. In addition, the expression of IL-15 receptor alpha (IL-15Ralpha) and membrane-bound IL-15 was assessed and the in vitro effects of IL-15 on CD69 and CD64 expression, interferon-gamma and TNF-alpha synthesis, respiratory burst induction and apoptosis were studied.
  
  
  RESULTS
  Serum levels of IL-15 were significantly increased in inactive and active patients with SLE. Accordingly, the in vitro synthesis and release of IL-15 by monocytes in response to IFN-gamma+lipopolysaccharide was significantly enhanced in SLE patients with active disease, as was the percentage of membrane-bound IL-15+ monocytes. On the other hand, enhanced basal expression of IL-15Ralpha was detected in leucocytes from SLE patients, with defective induction upon stimulation with phytohaemagglutinin or phorbol myristate acetate/ionomycin. Furthermore, diminished induction of CD69 expression and interferon-gamma and TNF-alpha synthesis by recombinant human IL-15 was detected in peripheral blood mononuclear cells from SLE, and there was defective induction of CD64 and priming for respiratory burst in neutrophils. The anti-apoptotic effect of IL-15 was diminished in leucocytes from SLE patients.
  
  
  CONCLUSIONS
  Our data indicate that there is enhanced synthesis of IL-15 by immune cells from SLE patients, with a poor response to this cytokine by different leucocyte subsets. This abnormal function of IL-15/IL-15Ralpha may contribute significantly to the pathogenesis of SLE.
authors.affiliation: Departamento de Inmunología, Facultad de Medicina, UASLP, San Luis Potosí, SLP, México.
authors.forename: L
authors.initials: L
authors.lastname: Baranda
authors.forename: H
authors.initials: H
authors.lastname: de la Fuente
authors.forename: E
authors.initials: E
authors.lastname: Layseca-Espinosa
authors.forename: D
authors.initials: D
authors.lastname: Portales-Pérez
authors.forename: P
authors.initials: P
authors.lastname: Niño-Moreno
authors.forename: G
authors.initials: G
authors.lastname: Valencia-Pacheco
authors.forename: C
authors.initials: C
authors.lastname: Abud-Mendoza
authors.forename: J
authors.initials: J
authors.lastname: Alcocer-Varela
authors.forename: R
authors.initials: R
authors.lastname: González-Amaro
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000097:blood; D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood; D017209:Apoptosis / Q000276:immunology; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006801:Humans; D019409:Interleukin-15 / Q000096:biosynthesis / Q000097:blood* / Q000276:immunology; D037181:Lectins, C-Type; D007962:Leukocytes / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008875:Middle Aged; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2 / Q000097:blood* / Q000276:immunology; D000099192:CD69 Antigens
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D016207:Cytokines; D019409:Interleukin-15; D037181:Lectins, C-Type; D053647:Receptors, Interleukin-15; D015375:Receptors, Interleukin-2; D000099192:CD69 Antigens; C508024:IL15RA protein, human